Approaches to relapse after allogeneic stem cell transplantation

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Relapse is the primary cause of mortality after allogeneic hematopoietic stem cell transplantation (HSCT).
• Despite advances in understanding the graft-versus-leukemia/tumor effect, relapse rates have not decreased in two decades.
• Limited effective treatment options exist for patients experiencing relapse post-allograft.

Purpose of the Study:

• To review current and emerging treatment strategies for relapse following allogeneic HSCT.
• To highlight the challenges and unmet needs in managing post-transplant relapse.

Main Methods:

• Systematic review of available literature on relapse treatment post-allogeneic HSCT.
• Analysis of current treatment modalities and investigation of novel therapeutic approaches.

Main Results:

• Standard treatments include withdrawal of immunosuppression, donor lymphocyte infusions, chemotherapy, and second HSCT, with variable outcomes.
• Investigational cellular therapies include disease-specific T-cells, alloreactive NK cells, and vaccination strategies.
• Emerging novel agents (tyrosine-kinase inhibitors, hypomethylating agents, etc.) show promise but require further validation.

Conclusions:

• Treatment for relapse after allogeneic HSCT is challenging, with generally poor outcomes.
• Significant research efforts are required to improve prevention and treatment strategies for relapse.
• Developing more effective therapies is crucial to reduce mortality in patients relapsing post-HSCT.